Treatment for extreme drug-resistant tuberculosis wins US government approval

  27 August 2019

The US Food and Drug Administration has approved a drug regimen to treat an extreme form of multi-drug-resistant tuberculosis (TB).

Nearly 90% of people infected with extensively drug-resistant (XDR) TB who took this treatment during a clinical trial recovered in 6 months. The average success rate for drug regimens currently used to treat XDR TB is around 34%

Further reading: Nature
Author(s): Amy Maxmen
Healthy Patients   Smart Innovations  
Back

OUR UNDERWRITERS

Unrestricted financial support by:

Antimicrobial Resistance Fighter Coalition

Bangalore Bioinnovation Centre

INTERNATIONAL FEDERATION PHARMACEUTICAL MANUFACTURERS & ASSOCIATIONS

BD





AMR NEWS

Every two weeks in your inbox

Because there should be one newsletter that brings together all One Health news related to antimicrobial resistance: AMR NEWS!

Subscribe

What is going on with AMR?
Stay tuned with remarkable global AMR news and developments!

Keep me informed